Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

BACKGROUND: Brigatinib is a central nervous system-active second-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a broad range of ALK rearrangements in patients with non-small cell lung cancer (NSCLC). The current study aimed to analyze the pooled effects and adverse events of bri...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Hao, Xuezhi, Zhang, Xin, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669367/
https://www.ncbi.nlm.nih.gov/pubmed/36408160
http://dx.doi.org/10.3389/fonc.2022.920709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669367/
https://www.ncbi.nlm.nih.gov/pubmed/36408160
http://dx.doi.org/10.3389/fonc.2022.920709

Ejemplares similares